Definitive Healthcare Corp. filings document the regulatory disclosures of a public healthcare data and analytics software company. Recent Form 8-K reports furnish quarterly and annual financial-result releases covering revenue, net loss, adjusted profitability measures, cash flow, guidance, and impairment-related disclosures tied to the company’s subscription-based commercial intelligence platform.
The filing record also includes definitive proxy materials for annual stockholder matters, board elections, executive compensation, equity awards, and governance practices. Other material-event filings document board and committee composition changes, executive-role and compensation arrangements, and the termination of a nominating agreement affecting director-designation rights.
Advent International entities reported beneficial ownership of Class A common stock of Definitive Healthcare Corp. The filing lists 62,493,676 shares under shared voting and dispositive power, representing 59.82% of Class A common stock based on 104,472,371 shares outstanding as of February 23, 2026. The statement is a joint Schedule 13G/A filing that identifies the specific Advent funds and related entities holding the shares and clarifies control relationships among the Advent reporting persons.
Definitive Healthcare Corp. reported a sharp net loss as it fully wrote off goodwill and faced softer demand. For the quarter ended March 31, 2026, revenue was $55.9 million, down from $59.2 million a year earlier, with subscription services contributing $53.6 million.
The company recorded a non‑cash goodwill impairment charge of $197.2 million, eliminating its remaining goodwill and driving a net loss of $192.4 million and a basic and diluted loss per share of $1.32. Operating cash flow remained positive at $11.6 million, and cash and cash equivalents totaled $157.6 million with short‑term investments of $20.4 million.
Management cited past sales execution challenges, macroeconomic pressure on smaller and life sciences customers, and elevated churn, which reduced the customer base to about 2,260 and Enterprise Customers to 495. The company also initiated a 2026 restructuring plan, cutting roughly 40 employees and recording $1.1 million in related charges to support margin improvement.
Definitive Healthcare Corp. reported Q1 2026 results with revenue of $55.9 million, down 6% from $59.2 million in Q1 2025. The company recorded a large GAAP net loss of $192.4 million, driven by $197.2 million of goodwill impairment, but generated positive non-GAAP profitability and cash flow.
Adjusted Net Income rose to $8.5 million and Adjusted EBITDA increased to $15.3 million, or 27% of revenue. Operating cash flow was $11.6 million and Unlevered Free Cash Flow was $18.0 million. Management highlighted performance at or above the high end of guidance and noted improving retention.
For full year 2026, the company expects revenue of $220.0–$226.0 million, Adjusted EBITDA of $55.0–$59.0 million (25%–26% margin), and Adjusted Net Income of $23.0–$27.0 million.
Definitive Healthcare Corp. executive chairman and major shareholder Jason Ronald Krantz reported a share disposition that was purely for tax purposes. On the vesting and settlement of previously reported RSUs, 12,166 shares of Class A common stock were withheld by the company at $0.99 per share to satisfy his tax withholding obligations, rather than being sold in the open market. After this transaction, Krantz directly holds 1,201,438 Class A shares and indirectly benefits from 450,000 shares held in a trust named DH Holdings (formerly the Jason R. Krantz 2009 Trust).
Definitive Healthcare Corp. Chief Financial Officer Casey Heller reported a small share disposition related to tax withholding. On May 1, 2026, 1,469 shares of Class A Common Stock were withheld at $0.99 per share to satisfy tax obligations upon vesting of previously reported RSUs. After this non‑market transaction, Heller directly holds 2,005,853 shares of Class A Common Stock.
Definitive Healthcare Corp. is asking stockholders to vote at its June 4, 2026 annual meeting on four key items. Stockholders will elect three Class II directors, ratify Deloitte & Touche LLP as independent auditor for 2026, and cast an advisory vote on executive pay.
The company also seeks approval to amend its 2021 Equity Incentive Plan to increase the share reserve by 15,000,000 shares of Class A common stock, from 30,972,789 to 45,972,789, supporting future equity grants to employees, directors, and consultants.
Definitive Healthcare Corp. reported that it has ended a prior governance arrangement with an affiliate of Spectrum. The company and SE VII DHC AIV, L.P. entered into a termination agreement on April 3, 2026 that permanently and irrevocably ended their 2021 Nominating Agreement.
That Nominating Agreement had allowed Spectrum, while it beneficially owned at least 5% of the company’s outstanding common stock, to designate one person for inclusion in the board slate (the “Spectrum Designee”). Jeff Haywood, the Spectrum Designee, resigned from the board on March 30, 2026, and the nominating rights have now been fully terminated.
Definitive Healthcare Corp. CEO Kevin Coop had 37,593 shares of Class A Common Stock withheld on April 1 to cover tax obligations tied to vesting RSUs. This was a tax-withholding disposition, not an open-market sale. After this event, he directly holds 5,078,872 shares.
Definitive Healthcare Corp. director and executive chairman Jason Ronald Krantz had 45,154 shares of Class A Common Stock withheld on April 1, 2026 at $1.09 per share to cover tax obligations tied to the vesting of previously reported RSUs. This was a tax-withholding disposition, not an open-market sale, and was satisfied by the issuer delivering shares for the liability.
After this event, Krantz directly held 1,213,604 shares of Class A Common Stock. He also beneficially owned an additional 450,000 shares held in trust by DH Holdings (f/k/a Jason R. Krantz 2009 Trust), of which he is the beneficiary.